Drugs / iodine I 131 metaiodobenzylguanidine
iodine I 131 metaiodobenzylguanidine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00790413 | Aug 2005 → Dec 2022 | neuroblastoma | Lund University Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00389766 | Jul 2008 | neuroblastoma | Children's Cancer and Leukaemia Group | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iodine I 131 metaiodobenzylguanidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00389766 ↗ |
| Known as | (131)I-MIBG | “We evaluated the feasibility and efficacy of using high-dose iodine-131-metaiodobenzylguanidine ((131)I-MIBG) followed by reduced-intensity conditioning (RIC) and...” PMID 19660720 ↗ Jul 2009 |
| Known as | iodine-131-metaiodobenzylguanidine | “High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.” PMID 19660720 ↗ Jul 2009 |
| Known as | MIBG | “Radioisotope therapy, such as iodine I 131 metaiodobenzylguanidine (MIBG), releases radiation that kills tumor cells.” NCT00389766 ↗ |
| Modality | Other / unclassified | “Radioisotope therapy, such as iodine I 131 metaiodobenzylguanidine (MIBG), releases radiation that kills tumor cells.” NCT00389766 ↗ |
| Route | Intravenous | “high-dose iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes on days 1 and 15” NCT00389766 ↗ |